A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 29, 2019

Primary Completion Date

June 28, 2019

Study Completion Date

June 28, 2019

Conditions
Migraine
Interventions
DRUG

"M207 3.8 mg Sled (two 1.9 mg patches made on a Sled coater, foil pouches)"

"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a Sled coater and packaged in foil pouches"

DRUG

"M207 3.8 mg MACAP (two 1.9 mg patches made on a MACAP coater, foil cups)"

"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a MACAP coater and packaged in foil cups"

DRUG

"M207 3.8 mg MiniMac (two 1.9 mg patches made on a MiniMac coater, foil cups"

"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a miniMac coater and packaged in foil pouches"

DRUG

Zolmitriptan 2.5 mg/0.1 mL nasal spray [ZOMIG] single dose

Zolmitriptan 2.5 mg/0.1 mL nasal spray \[ZOMIG\] single dose

Trial Locations (1)

85283

Celerion, Tempe

All Listed Sponsors
lead

Zosano Pharma Corporation

INDUSTRY

NCT03978403 - A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers | Biotech Hunter | Biotech Hunter